'Fully Engaged' docs more open to influence

Share this article:
A new study measuring physician engagement levels with reps found that prescribing behavior is influenced significantly by social chemistry.

The study, conducted by PeopleMetrics Rx, categorized physicians at four levels of engagement – “Fully Engaged,” “Engaged,” “On the Fence” and “Disengaged”–during atypical antipsychotic sales details. 

According to the study, the most effective reps formed personal relationships with physicians. Full engagement describes physicians that “enjoy the relationship [with a rep], would go out of their way to continue to meet with their sales rep, actively recommend the rep to others, and, given the choice, would keep their rep assigned to their practice.”

Study data suggests that fully engaged physicians prescribing a given product for 30% of patients, will increase scripts to 37% over six months. Disengaged physicians prescribing a product for 19% of patients will increase scripts to 20% over six months, the study found.

Additionally, fully engaged physicians spend more than twice as long speaking with reps per visit and meet with them twice as frequently as disengaged physicians.

"Measuring the emotional connection sales reps develop with their physicians is not typically monitored in standard sales force effectiveness research...yet we find that this emotional dimension is key in understanding physicians' perceptions toward their reps and the pharmaceutical company as a whole," said Gary White, EVP, PeopleMetrics Rx and lead researcher on the study, in a statement.

The study, titled Driving Physician Engagement and Productivity in Pharmaceutical Sales, included sales detailing for the following products: Bristol-Myers Squibb's Abilify; Pfizer's Geodon; Invega's Risperdal; AstraZeneca's Seroquel; and Eli Lilly's Zyprexa.
Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.